Teleflex Incorporated reported its fourth-quarter 2025 earnings on February 26, revealing a significant miss in both earnings per share (EPS) and revenue compared to forecasts. The company reported an ...

Teleflex (TFX) came out with quarterly earnings of $1.93 per share, missing the Zacks Consensus Estimate of $3.73 per share. This compares to earnings of $3.89 per share a year ago. These figures are ...

WAYNE, Pa. (AP) — WAYNE, Pa. (AP) — Teleflex Inc. (TFX) on Thursday reported a loss of $714.3 million in its fourth quarter. The Wayne, Pennsylvania-based company said it had a loss of $16.15 per ...

Boardrooms and advisory panels across pharma, biotech, medtech, and digital health were busy last month, with a string of appointments bringing deep commercial, scientific, and regulatory expertise to ...

WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its fourth quarter 2025 financial results and provide an operational update at 8:00 a.m. Eastern ...

Tejara Capital bought 69,700 Teleflex shares in the fourth quarter; the estimated trade size was $8.45 million based on quarterly average prices. Meanwhile, the quarter-end position value rose by ...

Teleflex's (NYSE: TFX) fourth-quarter 2024 earnings conference call, held on February 27, 2025, revealed significant strategic shifts for the medical device company. In a transformative announcement, ...

New York City-based Eos Management disclosed a new stake of 30,831 shares in Teleflex; the estimated transaction size was $3.76 million based on quarter-end values. The position change represented a 1 ...

Teleflex has parted ways with Liam Kelly, who had been at the helm of the provider of medical technologies since 2018. Teleflex on Thursday said it has named board member Stuart Randle interim ...

Teleflex cut its full-year revenue outlook for 2025, citing softer-than-expected demand and order delays. The medical-technologies company on Thursday said it now expects to report revenue of $3.27 ...

Teleflex Inc. announced that it has entered into definitive agreements to sell its OEM business as well as its acute care and interventional urology divisions to two different buyers. Intersurgical ...